Thyroid cancer is a common type of endocrine malignancy, and its incidence has been
steadily increasing in many regions of the world. Initiation and progression of thyroid cancer …

Substantial developments have occurred in the past 5–10 years in clinical translational
research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and …

Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …

Importance BRAF V600E andTERTpromoter mutations can coexist in papillary thyroid
cancer (PTC). This genetic duet was indicated to be involved in the aggressiveness of PTC …

Cellular senescence has been perceived as a barrier against carcinogenesis. However, the
senescence-associated secretory phenotype (SASP) of senescent cells can promote …

The incidence of differentiated thyroid cancer is increasing greatly in high-income countries.
Roughly 50% of this increase is attributable to the identification of intrathyroidal papillary …

In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged
progression-free survival (PFS) in patients with metastatic pancreatic/intestinal …

BACKGROUND: The effects of the BRAFV600E mutation on prognostic factors and poor
clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified. The …

Answer questions and earn CME/CNE Thyroid cancer exists in several forms. Differentiated
thyroid cancers include those with papillary and follicular histologies. These tumors exist …

In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …